Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating
Source: SeekingAlpha
2025-09-20 09:21:41 ET
The last time I spoke about Replimune ( REPL ) it was with respect to a Seeking Alpha article entitled " Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma . " With respect to this article, I noted the company's opportunity to potentially receive Accelerated Approval of its therapy RP1 in combination with Opdivo [nivolumab] for the treatment of patients with advanced melanoma. As an update since that article, the company did not receive U.S. marketing approval of RP1....
Read the full article on Seeking Alpha
For further details see:
Replimune: Further Uncertainty Of RP1 Warrants Move To 'Hold' Rating
Replimune Group Inc.
NASDAQ: REPL
REPL Trading
-6.4% G/L:
$7.02 Last:
1,610,656 Volume:
$7.66 Open:
REPL Latest News
February 03, 2026 08:00:00 am
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
December 18, 2025 08:00:00 am
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
REPL Stock Data
$646,543,607
51,607,887
0.33%
61
N/A
Biotechnology & Life Sciences
Healthcare
US
Woburn
